Clinical Trials Logo

Clinical Trial Summary

Neuromyelitis optica (NMO) is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. NMO is considered to have a B cell induced pathogenesis. Mitoxantrone (MITO, Novantrone®), a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, has been shown to primarily suppress the humoral response. We conducted a prospective 2-year study to evaluate the benefit of MITO in five relapsing NMO patients.


Clinical Trial Description

The treatment protocol consisted of monthly 12 mg/m2 MITO intravenous infusions for 6 months followed by 3 additional treatments every 3 months. Neurological assessment including the determination of the Expanded Disability Status Scale (EDSS) score was performed every 3 months and during relapses. Orbital, brain and spinal cord MRI was performed at baseline, 3, 6, 12, 18, and 24 months. Visual evoked potentials and ophthalmologic evaluations were performed at baseline and annually. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00304291
Study type Interventional
Source State University of New York at Buffalo
Contact
Status Completed
Phase Phase 4
Start date August 2001
Completion date May 2004

See also
  Status Clinical Trial Phase
Completed NCT02283671 - Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Phase 1
Recruiting NCT01024985 - Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct N/A
Recruiting NCT04601142 - Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT05573711 - Restless Legs Syndrome in People With Neuromyelitis Optica Spectrum Disorder
Not yet recruiting NCT06118398 - Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05566769 - Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD N/A
Withdrawn NCT03829566 - Autologous Transplant To End NMO Spectrum Disorder Phase 2/Phase 3
Recruiting NCT05403138 - Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Recruiting NCT05356858 - An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients Phase 2
Recruiting NCT05982925 - Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Terminated NCT02398994 - A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Phase 3
Withdrawn NCT02087813 - Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Phase 1
Terminated NCT01339455 - Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Phase 1/Phase 2
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Active, not recruiting NCT04614454 - High Frequency Impulse Therapy for Neuropathic Pain in NMOSD Phase 2
Recruiting NCT03370965 - Optic Neuritis Differential Diagnosis Study N/A
Completed NCT01777412 - Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Phase 1